Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data
增強了對 Proteograph 產品套件的訪問權限，並通過新的客戶數據展示了其強大功能
REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.
加利福尼亞州雷德伍德城，2024年2月29日（環球新聞專線）——將顛覆性蛋白質組學新平台商業化的領先生命科學公司Seer, Inc.（納斯達克股票代碼：SEER）今天公佈了截至2023年12月31日的第四季度和全年財務業績。
Recent Highlights
近期亮點
- Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter of 2022, and $16.7 million for the full year 2023, an increase of 8% over the full year 2022
- Shipped 23 instruments during 2023, bringing cumulative instruments shipped to 62 as of December 31, 2023
- Expanded internationally with the addition of four new distributors and partners
- First peer-reviewed customer publication in Nature Communications, demonstrating the power of the Proteograph in pQTL analysis
- Launched the Protein Discovery Catalog with over 10,000 proteins across 1,900 pathways to empower researchers
- Ended the year with approximately $373 million of cash, cash equivalents and investments
- 2023年第四季度實現收入440萬美元，比2022年第四季度下降4％，2023年全年收入1,670萬美元，比2022年全年增長8％
- 2023 年出貨了 23 臺儀器，使截至2023年12月31日的累計出貨量達到62臺
- 通過增加四家新的分銷商和合作夥伴向國際擴張
- 第一份經過同行評審的客戶出版物 《自然通訊》， 展示了 Proteograph 在 pqTL 分析中的力量
- 推出了蛋白質發現目錄，其中包含跨越1,900種途徑的10,000多種蛋白質，爲研究人員提供支持
- 年底擁有約3.73億美元的現金、現金等價物和投資
"In 2023, our customers continued to demonstrate the powerful biological insight that is uniquely possible by leveraging the Proteograph Product Suite. Recently, we saw our first customer study published in Nature Communications and we expect several more this year," said Omid Farokhzad, Chair and CEO. "Looking ahead, we are laser focused on translating the incredible performance of our platform and the uniqueness of the data it generates into widespread commercial adoption. I continue to be confident in the substantial long-term opportunity ahead and look forward to updating on our progress throughout 2024."
“2023年，我們的客戶繼續展示通過利用Proteograph產品套件所具有的獨特可能的強大生物學洞察力。最近，我們看到了發表在《客戶研究》中的第一份客戶研究 自然通訊 而且我們預計今年還會有幾個。” 董事長兼首席執行官奧米德·法羅赫扎德說。“展望未來，我們全神貫注於將我們平台的驚人性能及其生成的數據的獨特性轉化爲廣泛的商業應用。我仍然對未來的巨大長期機遇充滿信心，並期待在2024年期間了解我們的最新進展。”
Fourth Quarter 2023 Financial Results
2023 年第四季度財務業績
Revenue was $4.4 million for the three months ended December 31, 2023, a 3.6% decrease from $4.6 million for the three months ended December 31, 2022. This decrease was primarily due to a decrease in lease revenue related to SP100 instruments, partially offset by an increase in service revenue. Product revenue for the fourth quarter of 2023 was $3.0 million, including $366 thousand of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was $1.1 million, including $201 thousand of related party revenue, and primarily consisted of revenue related to the Seer Technology Access Center, and grant and other revenue was $258 thousand.
截至2023年12月31日的三個月，收入爲440萬美元，較截至2022年12月31日的三個月的460萬美元下降了3.6％。這一下降主要是由於與 SP100 儀器相關的租賃收入減少，但部分被服務收入的增加所抵消。2023 年第四季度的產品收入爲 300 萬美元，包括 36.6 萬美元的關聯方收入，包括 SP100 儀器和消耗品套件的銷售。服務收入爲110萬美元，包括20.1萬美元的關聯方收入，主要包括與Seer技術接入中心相關的收入，補助金和其他收入爲25.8萬美元。
Gross profit, inclusive of grant and other revenue, was $2.0 million and gross margin was 45.1% for the fourth quarter of 2023.
2023年第四季度，包括補助金和其他收入在內的毛利爲200萬美元，毛利率爲45.1％。
Operating expenses were $24.2 million for the fourth quarter of 2023, including $7.6 million of stock-based compensation, a decrease of 11% as compared to $27.2 million, including $8.2 million of stock-based compensation, for the corresponding prior year period. The decrease in expenses was primarily driven by a decrease in product development costs related to the Proteograph Product Suite, including employee compensation and other related expenses.
2023年第四季度的運營支出爲2420萬美元，包括760萬美元的股票薪酬，與去年同期的2720萬美元（包括820萬美元的股票薪酬）相比下降了11％。支出減少的主要原因是與Proteograph產品套件相關的產品開發成本的減少，包括員工薪酬和其他相關費用。
Net loss was $17.8 million for the fourth quarter of 2023, as compared to $22.5 million for the corresponding prior year period.
2023年第四季度的淨虧損爲1780萬美元，而去年同期的淨虧損爲2,250萬美元。
Full Year 2023 Financial Results
2023 年全年財務業績
Revenue was $16.7 million for the year ended December 31, 2023, an 8% increase from $15.5 million for the year ended December 31, 2022. Product revenue for the full year 2023 was $12.9 million, including $4.4 million of related party revenue. Service revenue was $2.3 million, including $241 thousand of related party revenue, and grant and other revenue was $1.5 million.
截至2023年12月31日的年度收入爲1,670萬美元，較截至2022年12月31日止年度的1,550萬美元增長了8％。2023年全年的產品收入爲1,290萬美元，其中包括440萬美元的關聯方收入。服務收入爲230萬美元，包括24.1萬美元的關聯方收入，補助金和其他收入爲150萬美元。
Gross profit, inclusive of grant and other revenue, was $8.5 million and gross margin was 51.1% for the full year 2023.
毛利，包括補助金和其他收入，爲850萬美元，2023年全年的毛利率爲51.1％。
Operating expenses were $112.0 million for the full year 2023, including $34.4 million of stock-based compensation, as compared to $104.3 million, including $33.7 million of stock-based compensation, for the corresponding prior year period.
2023年全年的運營支出爲1.12億美元，包括3440萬美元的股票薪酬，而去年同期爲1.043億美元，包括3,370萬美元的股票薪酬。
Net loss was $86.3 million for the full year 2023, as compared to $93.0 million for the corresponding prior year period.
2023年全年的淨虧損爲8,630萬美元，而去年同期的淨虧損爲9,300萬美元。
Cash, cash equivalents and investments were $373.1 million as of December 31, 2023.
截至2023年12月31日，現金、現金等價物和投資爲3.731億美元。
2024 Guidance
2024 年指導方針
Seer expects full year 2024 revenue to be in the range of $18 million to $20 million, representing growth of 14% at the midpoint over full year 2023.
Seer預計，2024年全年收入將在1,800萬美元至2000萬美元之間，相當於2023年全年中點增長14％。
Webcast Information
網絡直播信息
Seer will host a conference call to discuss the fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
Seer將於太平洋時間2024年2月29日星期四下午 1:30 /美國東部時間下午 4:30 主持電話會議，討論2023年第四季度和全年財務業績。電話會議的網絡直播可在以下網址觀看 http://investor.seer.bio。網絡直播將在活動結束後至少 90 天內存檔並可供重播。
About Seer
關於先知
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Seer 是一家生命科學公司，開發變革性產品，爲蛋白質組打開了新的門戶。Seer的Proteograph Product Suite是一種集成解決方案，包括專有的工程納米顆粒、消耗品、自動化儀器和軟件，可在短短几個小時內大規模進行深入、無偏見的蛋白質組學分析。Seer 設計的 Proteograph 工作流程既高效又易於使用，利用廣泛採用的實驗室儀器提供幾乎任何實驗室都可以採用的分散式解決方案。Seer 的 Proteograph 產品套件僅用於研究用途，不適用於診斷程序。欲了解更多信息，請訪問 www.seer.bio。
Forward Looking Statements
前瞻性陳述
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the Company's expectations for future results of operations and its financial position, business strategy, customer publications and adoption and outlook for fiscal year 2024. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission ("SEC") and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新聞稿包含經修訂的1995年《私人證券訴訟改革法》所指的 “前瞻性陳述”。此類前瞻性陳述基於Seer的信念和假設以及截至本新聞稿發佈之日其目前獲得的信息。前瞻性陳述可能涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致Seer的實際業績、業績或成就與前瞻性陳述所表達或暗示的業績、業績或成就存在重大差異。這些聲明包括但不限於有關公司對未來經營業績的預期及其財務狀況、業務戰略、客戶出版物以及2024財年的採用和展望的聲明。Seer向美國證券交易委員會（“SEC”）提交的文件以及西爾隨後不時向美國證券交易委員會提交的其他文件中對這些風險和其他風險進行了更全面的描述。除非法律要求，否則Seer沒有義務更新此類聲明以反映在聲明發表之日後發生的事件或存在的情況。
Investor Contact:
Carrie Mendivil
investor@seer.bio
投資者聯繫人：
Carrie Mendivil
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio
媒體聯繫人：
帕特里克·施密特
pr@seer.bio
|
Seer, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) | |||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Revenue: | |||||||||||||||||||
| Product | $ | 2,669 | $ | 1,431 | $ | 8,506 | $ | 8,557 | |||||||||||
| Service | 944 | 708 | 2,016 | 913 | |||||||||||||||
| Related party | 567 | 1,720 | 4,660 | 5,215 | |||||||||||||||
| Grant and other | 258 | 745 | 1,479 | 808 | |||||||||||||||
| Total revenue | 4,438 | 4,604 | 16,661 | 15,493 | |||||||||||||||
| Cost of revenue: | |||||||||||||||||||
| Product | 1,663 | 785 | 5,398 | 5,459 | |||||||||||||||
| Service | 390 | 446 | 685 | 495 | |||||||||||||||
| Related party | 204 | 624 | 1,430 | 1,989 | |||||||||||||||
| Grant and other | 180 | 457 | 642 | 457 | |||||||||||||||
| Total cost of revenue | 2,437 | 2,312 | 8,155 | 8,400 | |||||||||||||||
| Gross profit | 2,001 | 2,292 | 8,506 | 7,093 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Research and development | 11,165 | 12,631 | 53,019 | 45,797 | |||||||||||||||
| Selling, general and administrative | 13,068 | 14,612 | 58,950 | 58,531 | |||||||||||||||
| Total operating expenses | 24,233 | 27,243 | 111,969 | 104,328 | |||||||||||||||
| Loss from operations | (22,232) | (24,951) | (103,463) | (97,235) | |||||||||||||||
| Other income (expense): | |||||||||||||||||||
| Interest income | 4,720 | 2,498 | 17,764 | 4,602 | |||||||||||||||
| Other expense | (287) | (73) | (578) | (333) | |||||||||||||||
| Total other income | 4,433 | 2,425 | 17,186 | 4,269 | |||||||||||||||
| Net loss | $ | (17,799) | $ | (22,526) | $ | (86,277) | $ | (92,966) | |||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.28) | $ | (0.36) | $ | (1.35) | $ | (1.49) | |||||||||||
| Weighted-average common shares outstanding, basic and diluted | 64,157,125 | 62,805,423 | 63,850,490 | 62,433,613 | |||||||||||||||
| Seer, Inc. 合併運營報表 （以千計，股票和每股金額除外） | |||||||||||||||||||
| 截至12月31日的三個月 | 截至12月31日的財年 | ||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| 收入： | |||||||||||||||||||
| 產品 | $ | 2,669 | $ | 1,431 | $ | 8,506 | $ | 8,557 | |||||||||||
| 服務 | 944 | 708 | 2,016 | 913 | |||||||||||||||
| 關聯方 | 567 | 1,720 | 4,660 | 5,215 | |||||||||||||||
| 格蘭特等 | 258 | 745 | 1,479 | 808 | |||||||||||||||
| 總收入 | 4,438 | 4,604 | 16,661 | 15,493 | |||||||||||||||
| 收入成本： | |||||||||||||||||||
| 產品 | 1,663 | 785 | 5,398 | 5,459 | |||||||||||||||
| 服務 | 390 | 446 | 685 | 495 | |||||||||||||||
| 關聯方 | 204 | 624 | 1,430 | 1,989 | |||||||||||||||
| 格蘭特等 | 180 | 457 | 642 | 457 | |||||||||||||||
| 總收入成本 | 2,437 | 2,312 | 8,155 | 8,400 | |||||||||||||||
| 毛利 | 2,001 | 2,292 | 8,506 | 7,093 | |||||||||||||||
| 運營費用： | |||||||||||||||||||
| 研究和開發 | 11,165 | 12,631 | 53,019 | 45,797 | |||||||||||||||
| 銷售、一般和管理 | 13,068 | 14,612 | 58,950 | 58,531 | |||||||||||||||
| 運營費用總額 | 24,233 | 27,243 | 111,969 | 104,328 | |||||||||||||||
| 運營損失 | (22,232) | (24,951) | (103,463) | (97,235) | |||||||||||||||
| 其他收入（支出）： | |||||||||||||||||||
| 利息收入 | 4,720 | 2498 | 17,764 | 4,602 | |||||||||||||||
| 其他費用 | (287) | (73) | (578) | (333) | |||||||||||||||
| 其他收入總額 | 4,433 | 2,425 | 17,186 | 4,269 | |||||||||||||||
| 淨虧損 | $ | (17,799) | $ | (22,526) | $ | (86,277) | $ | (92,966) | |||||||||||
| 歸屬於普通股股東的每股淨虧損，基本虧損和攤薄後 | $ | (0.28) | $ | (0.36) | $ | (1.35) | $ | (1.49) | |||||||||||
| 已發行普通股、基本股和攤薄後加權平均值 | 64,157,125 | 62,805,423 | 63,850,490 | 62,433,613 | |||||||||||||||
|
Seer, Inc. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) | |||||||
| December 31, | |||||||
| 2023 | 2022 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 32,499 | $ | 53,208 | |||
| Short-term investments | 283,725 | 368,031 | |||||
| Accounts receivable, net | 4,831 | 4,315 | |||||
| Related party receivables | 559 | 1,804 | |||||
| Other receivables | 1,326 | 899 | |||||
| Inventory | 4,491 | 4,627 | |||||
| Prepaid expenses and other current assets | 3,082 | 2,098 | |||||
| Total current assets | 330,513 | 434,982 | |||||
| Long-term investments | 56,858 | 5,157 | |||||
| Operating lease right-of-use assets | 25,177 | 27,003 | |||||
| Property and equipment, net | 22,193 | 19,408 | |||||
| Restricted cash | 524 | 524 | |||||
| Other assets | 1,004 | 855 | |||||
| Total assets | $ | 436,269 | $ | 487,929 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,370 | $ | 2,104 | |||
| Accrued expenses | 9,212 | 8,298 | |||||
| Deferred revenue | 206 | 133 | |||||
| Operating lease liabilities, current | 2,295 | 1,842 | |||||
| Other current liabilities | 139 | 207 | |||||
| Total current liabilities | 13,222 | 12,584 | |||||
| Operating lease liabilities, net of current portion | 25,964 | 28,032 | |||||
| Other noncurrent liabilities | 179 | 320 | |||||
| Total liabilities | 39,365 | 40,936 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of December 31, 2023 and 2022; zero shares issued and outstanding as of December 31, 2023 and 2022 | — | — | |||||
| Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of December 31, 2023 and 2022; 60,253,707 and 59,366,077 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 1 | 1 | |||||
| Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of December 31, 2023 and 2022; 4,044,969 shares issued and outstanding as of December 31, 2023 and 2022 |
— | — | |||||
| Additional paid-in capital | 702,868 | 667,739 | |||||
| Accumulated other comprehensive loss | (192) | (1,251) | |||||
| Accumulated deficit | (305,773) | (219,496) | |||||
| Total stockholders' equity | 396,904 | 446,993 | |||||
| Total liabilities and stockholders' equity | $ | 436,269 | $ | 487,929 | |||
| Seer, Inc. 合併資產負債表 （以千計，股票和每股金額除外） | |||||||
| 十二月三十一日 | |||||||
| 2023 | 2022 | ||||||
| 資產 | |||||||
| 流動資產： | |||||||
| 現金和現金等價物 | $ | 32,499 | $ | 53,208 | |||
| 短期投資 | 283,725 | 368,031 | |||||
| 應收賬款，淨額 | 4,831 | 4,315 | |||||
| 關聯方應收款 | 559 | 1,804 | |||||
| 其他應收賬款 | 1,326 | 899 | |||||
| 庫存 | 4,491 | 4,627 | |||||
| 預付費用和其他流動資產 | 3,082 | 2,098 | |||||
| 流動資產總額 | 330,513 | 434,982 | |||||
| 長期投資 | 56,858 | 5,157 | |||||
| 經營租賃使用權資產 | 25,177 | 27,003 | |||||
| 財產和設備，淨額 | 22,193 | 19,408 | |||||
| 限制性現金 | 524 | 524 | |||||
| 其他資產 | 1,004 | 855 | |||||
| 總資產 | $ | 436,269 | $ | 487,929 | |||
| 負債和股東權益 | |||||||
| 流動負債： | |||||||
| 應付賬款 | $ | 1,370 | $ | 2,104 | |||
| 應計費用 | 9,212 | 8,298 | |||||
| 遞延收入 | 206 | 133 | |||||
| 經營租賃負債，當前 | 2,295 | 1,842 | |||||
| 其他流動負債 | 139 | 207 | |||||
| 流動負債總額 | 13,222 | 12,584 | |||||
| 經營租賃負債，扣除流動部分 | 25,964 | 28,032 | |||||
| 其他非流動負債 | 179 | 320 | |||||
| 負債總額 | 39,365 | 40,936 | |||||
| 承付款和意外開支 | |||||||
| 股東權益： | |||||||
| 優先股，面值0.00001美元；截至2023年12月31日和2022年12月31日已獲授權的500萬股；截至2023年12月31日和2022年12月31日已發行和流通的股票爲零 | — | — | |||||
| A類普通股，面值0.00001美元；截至2023年12月31日和2022年12月31日已授權94,000,000股；截至2023年12月31日和2022年12月31日分別已發行和流通的60,253,707股和59,366,077股股票 | 1 | 1 | |||||
| B 類普通股，面值0.00001美元；截至2023年12月31日和2022年12月31日已獲授權6,000,000股；4,044,969股 截至 2023 年 12 月 31 日和 2022 年 12 月 31 日已發行和未償還的 |
— | — | |||||
| 額外的實收資本 | 702,868 | 667,739 | |||||
| 累計其他綜合虧損 | (192) | (1,251) | |||||
| 累計赤字 | (305,773) | (219,496) | |||||
| 股東權益總額 | 396,904 | 446,993 | |||||
| 負債和股東權益總額 | $ | 436,269 | $ | 487,929 | |||